Survival prediction and adjuvant chemotherapy based on tumor marker for stage IB lung adenocarcinoma

Publication date: Available online 12 October 2019Source: The Annals of Thoracic SurgeryAuthor(s): Yiyang Wang, Difan Zheng, Tianxiang Chen, Jie Zhang, Feng Yao, Haiquan ChenAbstractBackgroundWe aimed to find out the prognosis of stage IB invasive lung adenocarcinoma according to perioperative tumor markers (TMs), especially carcinoembryonic antigen (CEA), and to determine whether TMs could guide adjuvant chemotherapy.MethodsStage IB adenocarcinoma patients were selected from two medical centers in Shanghai between January 2007 and December 2013. Perioperative TMs including preoperative and postoperative TMs were stratified into normal level, CEA normal and CEA elevated, respectively. Propensity score matching was analyzed for eliminating variable differences between chemotherapy and observation groups. Univariable and multivariable cox regressions were conducted to discovery the prognostically independent risk factors. Kaplan-Meier curves were plotted and testified by Log-rank test. Subgroup analysis was performed to investigate chemotherapy benefit according to postoperative TMs.ResultsPostoperative CEA elevated (HR=6.783, 95% CI 2.534-18.162, p
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research

Related Links:

Publication date: Available online 19 February 2020Source: European Journal of Surgical OncologyAuthor(s): Maximilian Weniger, Rainer C. Miksch, Patrick Maisonneuve, Jens Werner, Jan G. D’HaeseAbstractIntroductionSurgical resection improves survival in pancreatic ductal adenocarcinoma (PDAC) and adjuvant chemotherapy adds an additional survival-benefit. While surgical technique has improved in recent years, it remains unclear whether these improvements translate into a survival benefit independent of adjuvant chemotherapy. Thus, we aimed to clarify whether survival of patients who were treated with either Gemcitabine...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Abstract The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Conclusions: LTS is an innovative clinical parameter of toxicity burden, differential treatment-related TS in individual patient. LTS can evaluate pharmacogenomic biomarkers predictive relevance to select mGI patients fit for intensive treatments, at risk of limiting gastrointestinal toxicity.Trial Registrations: The trials were registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2007-004946-34, and Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2009- 016793-32.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, we evaluated the efficacy of anlotinib as third ‐ or further‐line treatment for patient with different histological types of NSCLC. In the ALTER0303 trial, 336 patients had the histological subtype of adenocarcinoma (ACC), 86 patients had the histological subtype of squamous cell carcinoma (SCC), and 15 patients had another subtype. Our findi ngs suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients. AbstractBackgroundAnlotinib showed significant survival benefits in advanced non ‐small cell lung cancer (NSCLC) patients as a thir...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionIn this paper, we present a robust approach for synthesizing a highly water-soluble [60]fullerene nanoconjugate with gemcitabine. The performed biological assays on pancreatic cancer cell lines demonstrated cytotoxic effects of nanoC60GEM, which were enhanced by the generation of reactive oxygen species after blue LED irradiation of synthesized fullerene nanomaterial.
Source: Cancer Nanotechnology - Category: Cancer & Oncology Source Type: research
Abstract Background: Positive results of randomized trials led to the introduction of FOLFIRINOX in 2012 and gemcitabine with nab-paclitaxel in 2015 for patients with metastatic pancreatic ductal adenocarcinoma. It is unknown to which extent these new chemotherapeutic regimens have been implemented in clinical practice and what the impact has been on overall survival.Material and methods: Patients diagnosed with metastatic pancreatic ductal adenocarcinoma between 2007-2016 were included from the population-based Netherlands Cancer Registry. Multilevel logistic regression and Cox regression analyses, adjusting for ...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
ConclusionHere, we highlighted the AKT pathway as an important regulatory pathway for Arl4c expression in lung cancer cells and identified HCPT as a promising drug for lung adenocarcinoma treatment that functioned by targeting Arl4c expression.
Source: Life Sciences - Category: Biology Source Type: research
Karamouzis Immune checkpoint inhibitors have revolutionized cancer treatment in the last decade. Despite the progress in immunotherapy, most pancreatic cancer patients still do not derive benefit when receiving immune-based therapies. Recently, resistance mechanisms to immune therapies have been mainly focused on tumor microenvironment properties. Pancreatic cancer is considered one of the most lethal and difficult to treat tumors due to its highly immunosuppressive and desmoplastic microenvironment. Low molecular weight heparins (LMWHs) have been used for the treatment and prevention of thromboembolic disease in the...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionsNeoadjuvant radiotherapy with 46  Gy and concomitant chemotherapy with paclitaxel and carboplatin for the treatment of locally advanced esophageal carcinoma is safe and effective. The results of this modified radiotherapy protocol are encouraging and should be considered in future patient treatment and study designs.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
Current antiangiogenic therapy is limited by its cytostatic property, scarce drug delivery to the tumor, and side toxicity. To address these limitations, we unveiled the role of ZEB1, a tumor endothelium–enriched zinc-finger transcription factor, during tumor progression. We discovered that the patients who had lung adenocarcinomas with high ZEB1 expression in tumor endothelium had increased prevalence of metastases and markedly reduced overall survival after the diagnosis of lung cancer. Endothelial ZEB1 deletion in tumor-bearing mice diminished tumor angiogenesis while eliciting persistent tumor vascular normalizat...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
More News: Adenocarcinoma | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy